BRPI0308274B8 - formulação de formoterol superfino - Google Patents

formulação de formoterol superfino

Info

Publication number
BRPI0308274B8
BRPI0308274B8 BRPI0308274A BR0308274A BRPI0308274B8 BR PI0308274 B8 BRPI0308274 B8 BR PI0308274B8 BR PI0308274 A BRPI0308274 A BR PI0308274A BR 0308274 A BR0308274 A BR 0308274A BR PI0308274 B8 BRPI0308274 B8 BR PI0308274B8
Authority
BR
Brazil
Prior art keywords
formulation
superfine
formoterol
relates
formoterol formulation
Prior art date
Application number
BRPI0308274A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0308274A (pt
BRPI0308274B1 (pt
Inventor
Ferraris Alessandra
John Meakin Brian
Andrew Lewis David
Ganderton David
Brambilla Gaetano
Jayne Davies Rebecca
Kathleen Church Tanya
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27790093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0308274(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02004786A external-priority patent/EP1340492A1/en
Priority claimed from EP02023589A external-priority patent/EP1415647A1/en
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR0308274A publication Critical patent/BR0308274A/pt
Publication of BRPI0308274B1 publication Critical patent/BRPI0308274B1/pt
Publication of BRPI0308274B8 publication Critical patent/BRPI0308274B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
BRPI0308274A 2002-03-01 2003-02-26 formulação de formoterol superfino BRPI0308274B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"
PCT/EP2003/001964 WO2003074024A1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation

Publications (3)

Publication Number Publication Date
BR0308274A BR0308274A (pt) 2004-12-28
BRPI0308274B1 BRPI0308274B1 (pt) 2018-10-30
BRPI0308274B8 true BRPI0308274B8 (pt) 2021-05-25

Family

ID=27790093

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0308274A BRPI0308274B8 (pt) 2002-03-01 2003-02-26 formulação de formoterol superfino
BR0308275-0A BR0308275A (pt) 2002-03-01 2003-02-27 Inaladores pressurizados dosimetrados contendo soluções de beta-2 agonistas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0308275-0A BR0308275A (pt) 2002-03-01 2003-02-27 Inaladores pressurizados dosimetrados contendo soluções de beta-2 agonistas

Country Status (36)

Country Link
US (4) US20050152846A1 (US20050154013A1-20050714-C00001.png)
EP (6) EP3494995B1 (US20050154013A1-20050714-C00001.png)
JP (3) JP2005523905A (US20050154013A1-20050714-C00001.png)
KR (2) KR100947409B1 (US20050154013A1-20050714-C00001.png)
CN (2) CN100398094C (US20050154013A1-20050714-C00001.png)
AR (2) AR038641A1 (US20050154013A1-20050714-C00001.png)
AT (1) ATE465712T1 (US20050154013A1-20050714-C00001.png)
AU (2) AU2003222753B2 (US20050154013A1-20050714-C00001.png)
BR (2) BRPI0308274B8 (US20050154013A1-20050714-C00001.png)
CA (2) CA2477881C (US20050154013A1-20050714-C00001.png)
CO (2) CO5611092A2 (US20050154013A1-20050714-C00001.png)
CY (4) CY1111133T1 (US20050154013A1-20050714-C00001.png)
DE (1) DE60332321D1 (US20050154013A1-20050714-C00001.png)
DK (4) DK3494995T3 (US20050154013A1-20050714-C00001.png)
EA (2) EA007735B1 (US20050154013A1-20050714-C00001.png)
ES (4) ES2780127T3 (US20050154013A1-20050714-C00001.png)
GE (2) GEP20063986B (US20050154013A1-20050714-C00001.png)
HK (1) HK1079425A1 (US20050154013A1-20050714-C00001.png)
HR (2) HRP20040753A2 (US20050154013A1-20050714-C00001.png)
HU (3) HUE044926T2 (US20050154013A1-20050714-C00001.png)
IL (3) IL163843A0 (US20050154013A1-20050714-C00001.png)
LT (3) LT3536344T (US20050154013A1-20050714-C00001.png)
MA (1) MA27175A1 (US20050154013A1-20050714-C00001.png)
ME (3) ME00077B (US20050154013A1-20050714-C00001.png)
MX (2) MXPA04008372A (US20050154013A1-20050714-C00001.png)
MY (2) MY143517A (US20050154013A1-20050714-C00001.png)
NO (2) NO342575B1 (US20050154013A1-20050714-C00001.png)
NZ (2) NZ535018A (US20050154013A1-20050714-C00001.png)
PE (2) PE20030824A1 (US20050154013A1-20050714-C00001.png)
PL (2) PL209212B1 (US20050154013A1-20050714-C00001.png)
PT (4) PT1480615E (US20050154013A1-20050714-C00001.png)
RS (2) RS52387B (US20050154013A1-20050714-C00001.png)
SI (4) SI1480615T1 (US20050154013A1-20050714-C00001.png)
TN (2) TNSN04147A1 (US20050154013A1-20050714-C00001.png)
TW (2) TWI347197B (US20050154013A1-20050714-C00001.png)
WO (2) WO2003074024A1 (US20050154013A1-20050714-C00001.png)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2005112902A2 (en) * 2004-05-13 2005-12-01 Chiesi Farmaceutici S.P.A. Medicinal aerosol formulation products with improved chemical stability
AU2005259523B2 (en) * 2004-07-02 2011-06-09 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5259193B2 (ja) * 2005-02-25 2013-08-07 チエシイ・ファルマセウテイシイ・エス・ペー・アー 加圧下にある用量計量型吸入器用の金属イオン封鎖剤を含む薬用エーロゾル配合物
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB2461752B (en) * 2008-07-14 2013-04-17 Neo Inhalation Products Ltd Metered dose inhaler
AU2009308412B2 (en) * 2008-10-23 2015-11-26 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EA021917B1 (ru) 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия астмы и copd
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
CA2805700A1 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions comprising r(+) budesonide and formoterol
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US20150297118A1 (en) * 2012-11-15 2015-10-22 Jp Respiratory Technology Ab Device and method for pulmonary function measurement
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
CN106667973A (zh) * 2017-01-22 2017-05-17 西咸新区世云工研坊生物科技有限公司 一种用于防雾霾损伤的组合物及其制备方法和喷剂
EP4096623A1 (en) 2020-01-28 2022-12-07 Chiesi Farmaceutici S.p.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
KR20220144361A (ko) 2020-02-20 2022-10-26 키에시 파르마슈티시 엣스. 피. 에이. 완충된 약제학적 제제를 포함하는 가압 정량 흡입기
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1244441B (it) * 1990-09-13 1994-07-15 Chiesi Farma Spa Dispositivo per l'inalazione boccale di farmaci aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
CA2116579A1 (en) * 1991-08-29 1993-03-18 Christoph Klein Medical device for inhaling doses of spray
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
WO1994013263A1 (en) 1992-12-09 1994-06-23 Jager Paul D Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
CA2361954C (en) * 1995-04-14 2003-07-08 Smithkline Beecham Corporation Metered dose inhaler for albuterol
EE04004B1 (et) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
CA2264524A1 (en) * 1996-10-04 1998-04-09 Norihiro Shinkai Patch
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6188933B1 (en) * 1997-05-12 2001-02-13 Light & Sound Design Ltd. Electronically controlled stage lighting system
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1862164A3 (de) * 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP1143930B8 (en) * 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6578125B2 (en) 2000-02-14 2003-06-10 Sanyo Electric Co., Ltd. Memory access circuit and memory access control circuit
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
CA2477881A1 (en) 2003-09-12
CN1638729A (zh) 2005-07-13
KR20040093079A (ko) 2004-11-04
CA2477885C (en) 2010-12-21
CA2477885A1 (en) 2003-09-12
PT1480615E (pt) 2010-06-16
MEP30108A (en) 2010-06-10
MA27175A1 (fr) 2005-01-03
ES2745064T3 (es) 2020-02-27
PT3536344T (pt) 2020-03-26
JP2010215637A (ja) 2010-09-30
US20050152846A1 (en) 2005-07-14
EP3494995A2 (en) 2019-06-12
KR100961603B1 (ko) 2010-06-04
EP1480615A1 (en) 2004-12-01
RS76604A (en) 2006-10-27
DE60332321D1 (de) 2010-06-10
RS52387B (en) 2013-02-28
JP2005524664A (ja) 2005-08-18
IL163843A0 (en) 2005-12-18
NO342575B1 (no) 2018-06-18
AU2003210370B2 (en) 2007-08-30
HRP20040752B1 (hr) 2012-10-31
AU2003210370C1 (en) 2008-03-13
PT3384931T (pt) 2019-09-26
NO20043626L (no) 2004-08-31
ATE465712T1 (de) 2010-05-15
NZ535018A (en) 2007-02-23
SI1480615T1 (sl) 2010-07-30
AU2003222753A1 (en) 2003-09-16
CO5611092A2 (es) 2006-02-28
EP2201964A2 (en) 2010-06-30
PE20030827A1 (es) 2003-11-06
EP3494995B1 (en) 2020-02-19
LT3536344T (lt) 2020-04-10
GEP20063986B (en) 2006-12-11
PL209212B1 (pl) 2011-08-31
BR0308274A (pt) 2004-12-28
US20050154013A1 (en) 2005-07-14
CO5611091A2 (es) 2006-02-28
ES2779273T3 (es) 2020-08-14
GEP20063876B (en) 2006-07-10
US8313732B2 (en) 2012-11-20
LT3494995T (lt) 2020-04-10
CY1122851T1 (el) 2021-05-05
DK3384931T3 (da) 2019-09-16
TW200303752A (en) 2003-09-16
RS76704A (en) 2007-02-05
TNSN04149A1 (en) 2007-03-12
AR038641A1 (es) 2005-01-19
EA007735B1 (ru) 2006-12-29
HUE049426T2 (hu) 2020-09-28
ES2342463T3 (es) 2010-07-07
LT3384931T (lt) 2019-09-25
WO2003074025A3 (en) 2003-12-24
MY143517A (en) 2011-05-31
HRP20040753A2 (en) 2004-12-31
DK3536344T3 (da) 2020-03-16
EP3536344A1 (en) 2019-09-11
DK3494995T3 (da) 2020-03-23
SI3536344T1 (sl) 2020-06-30
PE20030824A1 (es) 2003-11-07
EP1480615B1 (en) 2010-04-28
EA200401007A1 (ru) 2005-04-28
MXPA04008369A (es) 2004-11-26
TWI347197B (en) 2011-08-21
CY1122027T1 (el) 2020-10-14
US20110061651A1 (en) 2011-03-17
EA200401005A1 (ru) 2005-08-25
EP2201964A3 (en) 2013-01-23
NO20043625L (no) 2004-09-29
PL372173A1 (en) 2005-07-11
AU2003222753B2 (en) 2008-04-17
US20090263488A1 (en) 2009-10-22
BR0308275A (pt) 2004-12-28
WO2003074024A1 (en) 2003-09-12
EA008592B1 (ru) 2007-06-29
TNSN04147A1 (en) 2007-03-12
ES2780127T3 (es) 2020-08-24
PL372292A1 (en) 2005-07-11
WO2003074025A2 (en) 2003-09-12
EP3384931B1 (en) 2019-07-24
ME00077B (me) 2010-06-10
HUE048310T2 (hu) 2020-07-28
HUE044926T2 (hu) 2019-11-28
CN1638730A (zh) 2005-07-13
CY1122875T1 (el) 2021-05-05
HK1079425A1 (en) 2006-04-07
JP2005523905A (ja) 2005-08-11
CN100398094C (zh) 2008-07-02
MXPA04008372A (es) 2004-11-26
EP2201964B1 (en) 2018-08-08
BRPI0308274B1 (pt) 2018-10-30
TW200303767A (en) 2003-09-16
CA2477881C (en) 2011-02-01
EP3384931A1 (en) 2018-10-10
IL163844A0 (en) 2005-12-18
CY1111133T1 (el) 2015-06-11
MEP30208A (en) 2010-10-10
EP1480617A2 (en) 2004-12-01
PT3494995T (pt) 2020-03-30
EP3536344B1 (en) 2020-02-19
SI3494995T1 (sl) 2020-08-31
KR20040093080A (ko) 2004-11-04
MY137603A (en) 2009-02-27
AU2003210370A1 (en) 2003-09-16
IL163843A (en) 2011-08-31
DK1480615T3 (da) 2010-07-12
EP3494995A3 (en) 2019-07-24
HRP20040752A2 (en) 2004-12-31
NZ535017A (en) 2007-02-23
SI3384931T1 (sl) 2019-11-29
KR100947409B1 (ko) 2010-03-12
AR038644A1 (es) 2005-01-19

Similar Documents

Publication Publication Date Title
BRPI0308274B8 (pt) formulação de formoterol superfino
AR101593A2 (es) Formulación superfina de formoterol
BR0306663A (pt) Formulação de salmeterol superfino
ES2270806T3 (es) Combinaciones de formoterol y de una sal de tiotropio.
ECSP024268A (es) Nuevos polvos para inhalacion que contienen tiotropio
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
BRPI0511136A (pt) formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
ECSP055821A (es) Nueva formulacion pulverulenta que contiene tiotropio destinado a la inhalación
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
BRPI0416136A (pt) processo para a produção de sais de tiotrópio, sais de tiotrópio, bem como formulações de medicamentos contendo os mesmos
Kunkel et al. Respimat®(a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients
O'Callaghan et al. Salbutamol dry powder inhaler: efficacy, tolerability, and acceptability study
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
CN1724567B (zh) 一种稳定的重组人干扰素α1b水溶液
Nizovtseva Berodual® in the treatment of bronchial asthma
BRPI0415685A (pt) sais de tiotrópio, processos para sua produção, bem como formulações de medicamentos contendo os mesmos
BR122014030154B8 (pt) formulação farmacêutica e processo para preparar uma formulação farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/00, 31/167, 31/4704, 31/485, 45/06, 47/06, 47/10, 47/34, 9/00, 9/12, 9/72; A61P 11/00, 11/06, 11/08, 11/16, 43/00; C07D 215/26

Ipc: A61K 31/00 (2011.01), A61K 31/167 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: CIPLA LIMITED - PETICAO NO870190028945 DE 27/03/2019.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.010638/2021-62 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1064779-29.2021.4.01.3400 SUBJUDICE AUTOR: CHIESI FARMACEUTICI S.P.A. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI"